Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
Status:
Recruiting
Trial end date:
2024-12-03
Target enrollment:
Participant gender:
Summary
immune checkpoint inhibitor combined with recombinant human endostatin can improve the
3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe